We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
2α,3α-Epithio-5α-androstan-17β-yl 1-Methoxycyclopentyl Ether in the Treatment of Advanced Breast Cancer —A Preliminary Clinical Trial—.
- Authors
KUMAOKA, SOICHI; TAKATANI, OSAMU; YOSHIDA, MINORU; MIURA, SHIGETO; TAKAO, TETSUTO; HAMANAKA, YÜJI; IZUO, MASARU; OKADA, TADAKAZU
- Abstract
A new orally active anti-estrogenic steroid, 2α,3α-epithio-5α-androstan-17β-yl 1-methoxycyclopentyl ether (10364-S) was given to 41 advanced breast cancer patients. Most patients were given a daily dose of 20 mg. The study was preliminary and not a controlled trial using an already proven androgenic steroid. The remission rate on giving this compound to advanced breast cancer was 11/41 or 26.8% and the average duration of the remission was 10.5 months.Hoarseness (8/41, 19.5%) and hirsutism (5/41, 12.2%) were relatively often seen as virilizing side effects. No unfavorable effects on the hematopoietic organs, the liver or on calcium metabolism were recognized in the study.
- Publication
Japanese Journal of Clinical Oncology, 1974, Vol 4, Issue 1, p65
- ISSN
0368-2811
- Publication type
Article